Veracyte, Inc. (VCYT) Earnings Call Transcripts
Veracyte, Inc.'s Latest Earnings Call - June 1, 2026
In the second quarter of fiscal year 2026, Veracyte, Inc. (VCYT:US) reported significant advancements in its clinical offerings, particularly with the Prosigna test, following the positive results from the OPTIMA trial presented at the ASCO Annual Meeting. The trial demonstrated that over two-thirds of high-risk early-stage breast cancer patients could safely avoid chemotherapy without compromising outcomes, which management believes positions Prosigna as a new standard in breast cancer care. While specific revenue figures were not disclosed, management indicated that the launch of Prosigna as a laboratory-developed test (LDT) is set for June 8, 2026, and expressed confidence in its market adoption despite the absence of Medicare reimbursement at launch.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | (null) |
| EPS | (null) |
| Market Opportunity | 225,000 patients (positive) |
| Prosigna Launch Date | June 8, 2026 (positive) |
| NCCN Guideline Inclusion | (neutral) |
Guidance from management
Management indicated that they expect Prosigna to be a significant contributor to revenue growth over the coming years, despite the initial absence of Medicare reimbursement. They emphasized the importance of clinical evidence in driving adoption and reimbursement decisions.
What management said
Yes. So I think I understand your question. In the premenopausal patients population specifically, they are managed by the same physicians. I think the evidence is very, very compelling. I think the evidence, as we've said, is practice-changing. I think adoption there, there are a lot of eager patients and eager patients equally that want to see this test apply to them. I think this is going to be one of our main ent...
I think the OPTIMA results in general are a driver for that shift, including in the 1 to 3 nodal status as well because of both the combined performance of the OPTIMA results and also OPTIMA prelim. I think overall, what it demonstrates is that so many patients to both can avoid chemotherapy, and that's not just supranoposals. So yes, I think there's nothing else to highlight. I would take the OPTIMA results in and o...
What analysts pressed on
Analysts expressed concerns about the competitive landscape and the potential challenges in gaining market share against established tests like Oncotype. There were also questions regarding the timeline for NCCN guideline inclusion and how that would impact commercial traction.
Main topics on the call
- OPTIMA Trial Results — The OPTIMA trial demonstrated that Prosigna can safely guide treatment decisions, allowing over 66% of high-risk patients to avoid chemotherapy without compromising survival outcomes. Management stated, "Prosigna identif...
- Market Opportunity — Management highlighted a significant market opportunity with approximately 225,000 patients diagnosed annually with ER-positive HER2-negative breast cancer, all of whom are eligible for Prosigna testing. They believe tha...
- Commercial Launch Strategy — Veracyte is set to launch Prosigna as an LDT on June 8, 2026, with a focus on integrating it into clinical workflows. Management emphasized that they have made substantial investments in their commercial team and infrast...
- Guideline Inclusion Expectations — Management expressed confidence that the compelling data from the OPTIMA trial will lead to inclusion in NCCN guidelines, which they view as a catalyst for growth. They noted that previous guidelines have historically dr...
Read the full Veracyte, Inc. transcript (June 1, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Veracyte, Inc.
Veracyte, Inc. (VCYT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 53 calls on record spanning February 25, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 53 Veracyte, Inc. earnings call transcripts on record, spanning February 25, 2020 to July 30, 2026. Based on this history, Veracyte, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- VCYT
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 53
- First call
- February 25, 2020
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly